Key result
Chebulagic acid reduced the viral cytopathic effect in vitro and efficiently reduced mortality and clinical symptoms in mice challenged with a lethal dose of enterovirus 71.
Why the study?
Does chebulagic acid reduce viral cytopathic effect in vitro and mortality in mice infected with enterovirus 71?
Does chebulagic acid reduce viral cytopathic effect in vitro and mortality in mice infected with enterovirus 71?
Chebulagic acid demonstrates potential as a therapeutic agent against human enterovirus 71 by inhibiting viral replication and reducing mortality in a preclinical model.
Answers are grounded in this paper and cite their sources.
Should not yet change enterovirus 71 management; hypothesis-generating for chebulagic acid development.
Human enterovirus 71 is one of the major causative agents of hand, foot and mouth disease in children under six years of age. Presently, no vaccines or antiviral drugs have been clinically available to employ against EV71. In this study, we demonstrate that treatment with chebulagic acid reduced the viral cytopathic effect on rhabdomyosarcoma cells with an IC50 of 12.5 μg/mL. The utilization of the chebulagic acid treatment on mice challenged with a lethal dose of enterovirus 71 was able to efficiently reduce mortality and relieve clinical symptoms through the inhibition of viral replication. Chebulagic acid may represent a potential therapeutic agent to control infections to enterovirus 71.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2013) studied Human enterovirus 71 infection. Chebulagic acid was evaluated on Viral cytopathic effect (in vitro) and mortality/clinical symptoms (in vivo). Chebulagic acid reduced the viral cytopathic effect in vitro and efficiently reduced mortality and clinical symptoms in mice challenged with a lethal dose of enterovirus 71.
Synapse has enriched 10 related papers. Consider them for comparative context: